The European Association of Urology and Elsevier are proud to present URO ONCO, the online educational platform for all healthcare professionals in uro-oncology.
URO ONCO provides up-to-date information on developments in the field of urological malignancies. With urological tumours presenting three of the ten most commonly found cancers, the need for up-to-date cancer management knowledge is essential for urologists
Latest Headlines in Prostate
Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients
European Urology 2015 Jan;67(1):23-9
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials
Ann Oncol. 2015 Apr;26(4):743-9.Abstract BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR), a marker of host inflammation, has been associated with poor outcome in several solid...
Latest Headlines in Bladder
Enhanced Recovery Pathways Versus Standard Care After Cystectomy: A Meta-analysis of the Effect on Perioperative Outcomes
Eur Urol. 2016 Dec;70(6):995-1003.
Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy
Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, et al.J Urol. 2016 Dec;196(6):1627-1633
Optical Coherence Tomography as a Tool for In Vivo Staging and Grading of Upper Urinary Tract Urothelial Carcinoma: A Study of Diagnostic Accuracy
Bus MT, de Bruin DM, Faber DJ, Kamphuis GM, Zondervan PJ, Laguna-Pes MP, et al.J Urol. 2016 Dec;196(6):1749-1755
Latest Headlines in Kidney
Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Zaid HB, Parker WP, Safdar NS, Gershman B, Erwin PJ, Murad MH, et al.J Urol. 2017 Jan;197(1):44-49
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)
BJU Int. 2014 Oct;114(Suppl 4):2Abstract Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, has clinical activity in mRCC. VEGF TKIs suppress regulatory...
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma
European Urology, Volume 68, Issue 1, July 2015, Pages 154 - 160
EAU 2017 Scientific Programme and Sessions
View the Scientific Programme and Sessions of the 2017 EAU Annual Congress, Munich, Germany.
5 most popular videos
5 most popular articles
- Mar 20177Mar 201710
European Society for Translational Medicine (EUSTM)ViennaVienna, Austria
- Mar 20179Mar 201711
Kantonsspital St. Gallen, Oncology and HematologyHotel EinsteinSt. Gallen, Switzerland
- Mar 201715Mar 201719
Leiden University Medical CenterLeiden University Medical CenterLeiden, Netherlands